DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia
- University of Exeter, United Kingdom
- University College London, United Kingdom
- University Medical Center Utrecht, Netherlands
- Trinity College Dublin, Ireland
- King's College London, United Kingdom
- University College Cork, Ireland
- National University of Ireland Galway, Ireland
- University of Oxford, United Kingdom
- Karolinska Institutet, Sweden
- Icahn School of Medicine at Mount Sinai, United States
- University of Helsinki/FIMM, Finland
- Maastricht University, Netherlands
- Royal College of Surgeons in Ireland, Ireland
- University of the Highlands and Islands, United Kingdom
- Jena University Hospital, Germany
- Cardiff University, United Kingdom
- Maastricht University Medical Centre, Netherlands
- University of Aberdeen, United Kingdom
- Finnish Institute for Health and Welfare, Finland
- Bilkent University, Turkey
- University of North Carolina at Chapel Hill, United States
- Eli Lilly and Company, United Kingdom
- University of Essex, United Kingdom
Abstract
We performed a systematic analysis of blood DNA methylation profiles from 4,483 participants from seven independent cohorts identifying differentially methylated positions (DMPs) associated with psychosis, schizophrenia and treatment-resistant schizophrenia. Psychosis cases were characterized by significant differences in measures of blood cell proportions and elevated smoking exposure derived from the DNA methylation data, with the largest differences seen in treatment-resistant schizophrenia patients. We implemented a stringent pipeline to meta-analyze epigenome-wide association study (EWAS) results across datasets, identifying 95 DMPs associated with psychosis and 1,048 DMPs associated with schizophrenia, with evidence of colocalization to regions nominated by genetic association studies of disease. Many schizophrenia-associated DNA methylation differences were only present in patients with treatment-resistant schizophrenia, potentially reflecting exposure to the atypical antipsychotic clozapine. Our results highlight how DNA methylation data can be leveraged to identify physiological (e.g., differential cell counts) and environmental (e.g., smoking) factors associated with psychosis and molecular biomarkers of treatment-resistant schizophrenia.
Data availability
Raw and processed data for the UCL, Aberdeen and Dublin cohorts are available through GEO accession numbers GSE84727, GSE80417, and GSE147221 respectively.
Article and author information
Author details
Funding
Medical Research Council (MR/K013807/1)
- Jonathan Mill
Medical Research Council (MR/R005176/1)
- Jonathan Mill
Medical Research Council (MR/M008924/1)
- Jonathan Mill
Karolinska Institutet (ALF 20090183)
- Christina M Hultman
Karolinska Institutet (ALF 20100305)
- Christina M Hultman
National Institutes of Health (R01 MH52857)
- Christina M Hultman
National Institute of Mental Health (R01MH077139)
- Patrick Sullivan
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Margaret M McCarthy, University of Maryland School of Medicine, United States
Version history
- Received: May 1, 2020
- Accepted: February 23, 2021
- Accepted Manuscript published: February 26, 2021 (version 1)
- Version of Record published: March 29, 2021 (version 2)
Copyright
© 2021, Hannon et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,520
- views
-
- 533
- downloads
-
- 70
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia
eLife 10:e58430.
https://doi.org/10.7554/eLife.58430
Further reading
-
- Cancer Biology
- Genetics and Genomics
Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.
-
- Computational and Systems Biology
- Genetics and Genomics
We propose a new framework for human genetic association studies: at each locus, a deep learning model (in this study, Sei) is used to calculate the functional genomic activity score for two haplotypes per individual. This score, defined as the Haplotype Function Score (HFS), replaces the original genotype in association studies. Applying the HFS framework to 14 complex traits in the UK Biobank, we identified 3619 independent HFS–trait associations with a significance of p < 5 × 10−8. Fine-mapping revealed 2699 causal associations, corresponding to a median increase of 63 causal findings per trait compared with single-nucleotide polymorphism (SNP)-based analysis. HFS-based enrichment analysis uncovered 727 pathway–trait associations and 153 tissue–trait associations with strong biological interpretability, including ‘circadian pathway-chronotype’ and ‘arachidonic acid-intelligence’. Lastly, we applied least absolute shrinkage and selection operator (LASSO) regression to integrate HFS prediction score with SNP-based polygenic risk scores, which showed an improvement of 16.1–39.8% in cross-ancestry polygenic prediction. We concluded that HFS is a promising strategy for understanding the genetic basis of human complex traits.
